Baseline immunoreactivity before pregnancy and poly(I:C) dose combine to dictate susceptibility and resilience of offspring to maternal immune activation.


Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
08 2020
Historique:
received: 07 01 2020
revised: 19 04 2020
accepted: 22 04 2020
pubmed: 27 4 2020
medline: 7 4 2021
entrez: 27 4 2020
Statut: ppublish

Résumé

Despite the potential of rodent models of maternal immune activation (MIA) to identify new biomarkers and therapeutic interventions for a range of psychiatric disorders, current approaches using these models ignore two of the most important aspects of this risk factor for human disease: (i) most pregnancies are resilient to maternal viral infection and (ii) susceptible pregnancies can lead to different combinations of phenotypes in offspring. Here, we report two new sources of variability-the baseline immunoreactivity (BIR) of isogenic females prior to pregnancy and differences in immune responses in C57BL/6 dams across vendors-that contribute to resilience and susceptibility to distinct combinations of behavioral and biological outcomes in offspring. Similar to the variable effects of human maternal infection, MIA in mice does not cause disease-related phenotypes in all pregnancies and a combination of poly(I:C) dose and BIR predicts susceptibility and resilience of pregnancies to aberrant repetitive behaviors and alterations in striatal protein levels in offspring. Even more surprising is that the intermediate levels of BIR and poly(I:C) dose are most detrimental to offspring, with higher BIR and poly(I:C) doses conferring resilience to measured phenotypes in offspring. Importantly, we identify the BIR of female mice as a biomarker before pregnancy that predicts which dams will be most at risk as well as biomarkers in the brains of newborn offspring that correlate with changes in repetitive behaviors. Together, our results highlight considerations for optimizing MIA protocols to enhance rigor and reproducibility and reveal new factors that drive susceptibility of some pregnancies and resilience of others to MIA-induced abnormalities in offspring.

Identifiants

pubmed: 32335198
pii: S0889-1591(20)30020-9
doi: 10.1016/j.bbi.2020.04.061
pmc: PMC7415552
mid: NIHMS1592387
pii:
doi:

Substances chimiques

Poly I-C O84C90HH2L

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-630

Subventions

Organisme : NIMH NIH HHS
ID : P50 MH106438
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH116681
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH112507
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD079125
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Myka L Estes (ML)

Center for Neuroscience, University of California, Davis, United States.

Kathryn Prendergast (K)

Center for Neuroscience, University of California, Davis, United States.

Jeremy A MacMahon (JA)

Center for Neuroscience, University of California, Davis, United States.

Scott Cameron (S)

Center for Neuroscience, University of California, Davis, United States.

John Paul Aboubechara (JP)

Center for Neuroscience, University of California, Davis, United States.

Kathleen Farrelly (K)

Center for Neuroscience, University of California, Davis, United States.

Gabrielle L Sell (GL)

Center for Neuroscience, University of California, Davis, United States.

Lori Haapanen (L)

Department of Internal Medicine, University of California, Davis, United States.

Joseph D Schauer (JD)

Department of Internal Medicine, University of California, Davis, United States.

Aurora Horta (A)

Center for Neuroscience, University of California, Davis, United States.

Ida C Shaffer (IC)

Center for Neuroscience, University of California, Davis, United States.

Catherine T Le (CT)

Center for Neuroscience, University of California, Davis, United States; Department of Dermatology, University of California, Davis, United States.

Greg N Kincheloe (GN)

Center for Neuroscience, University of California, Davis, United States.

Danielle John Tan (DJ)

Center for Neuroscience, University of California, Davis, United States.

Deborah van der List (D)

Center for Neuroscience, University of California, Davis, United States.

Melissa D Bauman (MD)

Dept. of Psychiatry, University of California, Davis, United States.

Cameron S Carter (CS)

Center for Neuroscience, University of California, Davis, United States; Dept. of Psychiatry, University of California, Davis, United States; Imaging Research Center, University of California, Davis, United States.

Judy Van de Water (J)

Department of Internal Medicine, University of California, Davis, United States.

A Kimberley McAllister (AK)

Center for Neuroscience, University of California, Davis, United States. Electronic address: kmcallister@ucdavis.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH